Sance Laboratories Private Limited

Sance Laboratories Private Limited, established on September 20, 2001, is a privately held Indian pharmaceutical company specializing in the manufacturing and export of cephalosporin antibiotic formulations. The company is headquartered in Kottayam, Kerala, India, with its registered office located at VI/51B, Elappunkal Junction, Kozhuvanal P.O., Pala, Kottayam District, Kerala 686573.

The company is classified as a private limited entity under the Corporate Identification Number (CIN) U24231KL2001PTC014957. As of the latest available financial data, Sance Laboratories has an authorized share capital of ₹4,00,00,000 and a paid-up capital of ₹3,95,99,970. In the fiscal year ending March 31, 2025, the company reported a 15.98% increase in total revenue, a 12.85% rise in profit, and a 17.51% growth in net worth, indicating robust financial health.

Sance Laboratories employs a dedicated workforce across various departments, including Quality Assurance, Production, Quality Control, Formulation & Development, Engineering, Finance, and Administration. The company's website, sancepharma.com, provides further insights into its operations and product offerings.

Sance Laboratories operates a state-of-the-art manufacturing facility located in Kottayam, Kerala, India. The plant is designed to produce a range of cephalosporin antibiotic formulations, including dry powder for injections, tablets, capsules, dry syrups, and sachets. The facility is built over a total land area of 1.5 acres, with a built-up area of 64,000 square feet, and is equipped with modern machinery to ensure high-quality production.

The manufacturing plant has a monthly production capacity of 17 million tablets, 4 million capsules, 0.25 million bottles of dry syrup, and 1.5 million vials of dry powder injections, based on an 8-hour single-shift operation. The facility adheres to stringent quality control measures and complies with international standards, including WHO-GMP, ISO 45001:2018, and ISO 14001:2015 certifications.

Sance Laboratories is led by a team of experienced professionals committed to the company's growth and operational excellence. The key executives include:

• Manoj Joseph: Managing Director, appointed on September 20, 2001.

• Jatin Joseph: Director, appointed on September 20, 2001.

• Valsamma Joseph: Director, appointed on September 20, 2001.

• Thommas Paul: Whole-Time Director, appointed on August 26, 2021.

These leaders bring a wealth of experience and strategic vision to Sance Laboratories, driving its mission to deliver high-quality pharmaceutical products globally.

Sance Laboratories has established a significant presence in various regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained approvals from multiple international regulatory bodies, such as the World Health Organization (WHO), Therapeutic Goods Administration (TGA) of Australia, Medicines and Healthcare products Regulatory Agency (MHRA) of the UK, and ANVISA of Brazil.

In the United States, Sance Laboratories has registered its manufacturing facility with the Food and Drug Administration (FDA), enabling the export of its products to the U.S. market. The company has also secured approvals from the FDA of Ghana and the Ministry of Health of Sri Lanka, further expanding its reach in these regions.

Sance Laboratories' adherence to Good Manufacturing Practices (GMP) and its commitment to quality have facilitated its entry into these regulated markets, underscoring its capability to meet international standards.

Sance Laboratories has strategically expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's products are available in over 50 countries across these regions, including Nigeria, Uganda, Tanzania, Zimbabwe, Kenya, Ghana, Namibia, Sri Lanka, the Philippines, Yemen, and Sudan.

The company's adherence to international standards, such as WHO-GMP, ISO 45001:2018, and ISO 14001:2015 certifications, has facilitated its entry into these markets. Additionally, Sance Laboratories' compliance with the Pharmaceutical Inspection Co-operation Scheme (PIC/S) standards has enabled it to meet the regulatory requirements of various countries, enhancing its global reach.

Sance Laboratories has adopted a diversified geographic strategy, establishing a presence in both regulated and emerging markets. This approach mitigates concentration risk and leverages growth opportunities across different regions. The company's expansion into over 50 countries, including those in Africa, Latin America, and Southeast Asia, demonstrates its commitment to global outreach.

By adhering to international quality standards and obtaining necessary certifications, Sance Laboratories has positioned itself as a reliable supplier in diverse markets. The company's strategic direction focuses on maintaining high-quality manufacturing processes while expanding its global footprint.

Sance Laboratories has registered its manufacturing facility with the U.S. Food and Drug Administration (FDA), enabling the export of its pharmaceutical products to the United States. The company has also secured approvals from the FDA of Ghana and the Ministry of Health of Sri Lanka, further expanding its reach in these regions.

The company's adherence to Good Manufacturing Practices (GMP) and its commitment to quality have facilitated its entry into these regulated markets, underscoring its capability to meet international standards.

Sance Laboratories has obtained certifications from the World Health Organization (WHO) for Good Manufacturing Practices (GMP), ISO 45001:2018, and ISO 14001:2015. These certifications demonstrate the company's commitment to maintaining high-quality manufacturing processes and environmental management systems.

The company's compliance with WHO-GMP standards has facilitated its entry into various international markets, including those in Africa, Latin America, and Southeast Asia. Additionally, Sance Laboratories' adherence to international standards, such as ISO 45001:2018 and ISO 14001:2015, underscores its dedication to quality and environmental management.

Sance Laboratories holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company's manufacturing facility is registered with the CDSCO, ensuring compliance with national standards for pharmaceutical manufacturing.

The company's adherence to CDSCO regulations and its commitment to quality have facilitated its operations within India and its export activities to various international markets.

As of March 28, 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to Sance Laboratories by regulatory authorities. This absence suggests that the company maintains a strong compliance record with regulatory agencies.

Sance Laboratories operates in the competitive cephalosporin antibiotic market, facing competition from both domestic and international pharmaceutical companies. While specific market share data is not publicly available, the company's focus on high-quality manufacturing and adherence to international standards positions it favorably in the market.

The company's expansion into over 50 countries, including those in Africa, Latin America, and Southeast Asia, demonstrates its ability to compete effectively in diverse markets.

Sance Laboratories' key differentiators include its specialization in cephalosporin antibiotic formulations, adherence to international quality standards such as WHO-GMP, ISO 45001:2018, and ISO 14001:2015, and its commitment to timely delivery without compromising on quality, safety, and efficacy.

Sance Laboratories' current strategic direction focuses